Halozyme Therapeutics Inc HALO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Halozyme Appoints David Ramsay as President Drug Delivery
-
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
-
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
-
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets
-
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
-
Halozyme to Report First Quarter 2026 Financial and Operating Results
-
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
-
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case — Update
Trading Information
- Previous Close Price
- $78.62
- Day Range
- $75.33–79.19
- 52-Week Range
- $55.64–82.26
- Bid/Ask
- $75.00 / $77.15
- Shares Outstanding
- 118.61M
- Market Cap
- $9.04B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 17.66
- Price/Sales
- 6.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 3.79%
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 423
- Website
- https://www.halozyme.com
Valuation
|
Metric
|
HALO
|
|---|---|
Price/Earnings (Normalized) | 17.66 |
Price/Book Value | 44.02 |
Price/Sales | 6.65 |
Price/Cash Flow | 11.62 |
Price/Earnings
HALO
Financial Strength
|
Metric
|
HALO
|
|---|---|
Quick Ratio | 2.14 |
Current Ratio | 2.76 |
Interest Coverage | 27.34 |
Quick Ratio
HALO
Profitability
|
Metric
|
HALO
|
|---|---|
Return on Assets (Normalized) | 26.72% |
Return on Equity (Normalized) | 196.45% |
Return on Invested Capital (Normalized) | 30.62% |
Return on Assets
HALO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%f^>r@b | LOCK|^t@YS | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#P&@<h | LOCK|SYYq | $70B | |||
| argenx SE ADR
ARGX
| LOCK|cx&Bq>x | LOCK|Z@& | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|SyKT^dx | LOCK|Xn#@ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|M$p!!j | LOCK|FlP | $36B | |||
| Moderna Inc
MRNA
| LOCK|JF&kd% | LOCK|nY | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|nlL@F>sQ | LOCK|<x&W@ | $25B | |||
| Incyte Corp
INCY
| LOCK|X$#qV$ | LOCK|MwT | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|QXzWW&H | LOCK|@^ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$@^KR$N | LOCK|?V | $17B |
United States